Navigation Links
Independent Physician Surveys Show if Approved, MF101 Could Become First-Line Treatment for Menopause Symptoms
Date:3/10/2008

EMERYVILLE, Calif., March 10 /PRNewswire-FirstCall/ -- Bionovo, Inc. (Nasdaq: BNVI) announced today results from two independent physician surveys which showed MF101 could become first-line treatment for menopausal vasomotor symptoms (hot flashes). In both qualitative and quantitative studies, 124 physicians board certified in internal medicine or obstetrics and gynecology specializing in the treatment of menopause reported MF101, if approved, would be their drug of choice for the treatment of hot flashes. In addition, 92% of physicians reported they would prescribe MF101 before prescribing an antidepressant agent for hot flashes.

"These results confirm what we have believed for over a decade. Both physicians and women are eagerly awaiting a safe and new alternative drug for the treatment of menopausal symptoms," said Mary Tagliaferri, M.D., Bionovo's President and CMO. "The multiple medical risks associated with estrogen therapies make these drugs undesirable, and the antidepressant agents currently used off label for this indication are poorly tolerated due to their many side effects. In contrast, our lead drug candidate, MF101, showed in a Phase 2 study that it is effective at alleviating hot flashes and is extremely well tolerated due to a very favorable safety profile."

In addition to placing MF101 at the top of the list of treatment options for menopausal symptoms, physicians also reported the following:
-- The accepted threshold for efficacy of a drug for vasomotor symptoms is

a 58% reduction in moderate to severe hot flashes, and,

-- The number one concern for women when considering treatment options for

menopausal symptoms is the risk of cancer.

-- Many women have foregone treatment of hot flashes, even moderate to

severe hot flashes, because of the side effects and risks of current

treatments.

"These independent physician studies provide us with further evidence that if available, MF101 can be a blockbuster drug once it hits the market," said Isaac Cohen, O.M.D., Chairman and CEO of Bionovo. "A safe and effective drug should be able to earn a large share of the $6-7 Billion of demand that existed in the past for this indication."

Complete results from the independent physician surveys are being prepared for publication.

Bionovo, Inc.

Bionovo is a pharmaceutical company focused on the discovery and development of safe and effective treatments for women's health and cancer, markets with significant unmet needs and billions in potential annual revenue. The company applies its expertise in the biology of menopause and cancer to design new drugs derived from botanical sources which have novel mechanisms of action. Based on the results of early and mid-stage clinical trials, Bionovo believes they have discovered new classes of drug candidates within their rich pipeline with the potential to be leaders in their markets. Bionovo is headquartered in Emeryville, California and is traded on the NASDAQ Capital Market under the symbol, "BNVI". For more information about Bionovo and its programs, visit: http://www.bionovo.com.

Forward Looking Statements

This release contains certain forward-looking statements relating to the business of Bionovo, Inc. that can be identified by the use of forward-looking terminology such as "believes," "expects," or similar expressions. Such forward-looking statements involve known and unknown risks and uncertainties, including uncertainties relating to product development, efficacy and safety, regulatory actions or delays, the ability to obtain or maintain patent or other proprietary intellectual property protection, market acceptance, physician acceptance, third party reimbursement, future capital requirements, competition in general and other factors that may cause actual results to be materially different from those described herein as anticipated, believed, estimated or expected. Certain of these risks and uncertainties are or will be described in greater detail in our filings with the Securities and Exchange Commission, which are available at http://www.sec.gov. Bionovo, Inc. is under no obligation (and expressly disclaims any such obligation) to update or alter its forward-looking statements whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Bionovo, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Independent Clinical Results Confirm Up to a 7-Centimeter Reduction in Body Circumference Using UltraShape(TM) Non-Invasive Fat Reduction and Body Contouring System
2. Facet Solutions AFRS(TM) Demonstrates Biomechanical Advantages Over Dynamic Stabilization in Independent Testing
3. Video: New Research Discovers Independent Brain Networks Control Human Walking
4. ISTA Pharmaceuticals Announces Physician-Sponsored Clinical Study of Xibrom(TM) Combination Therapy with Lucentis(R)
5. Physicians Reconsider Implications of Enhance Trial
6. ReachMD Broadcasts First-of-its-Kind Physician Peer-Peer Discussion on ENHANCE Trial
7. Physicians Will Benefit from Medical Software Advice Website
8. Leading Physicians Present Interim Results from Multi-Center Studies of VNUS ClosureFAST Catheter at VEITHsymposium
9. Bayer Issues Additional Guidance to Physicians on Trasylol(R)
10. Mayo Clinic Physicians Report Findings from Research on Sleep Disorders
11. St. Jude Finds Molecule That Could Improve Cancer Vaccine and Therapy for Other Diseases
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/9/2017)... INDIANAPOLIS , June 9, 2017 /PRNewswire/ ... diabetes. In a further effort to help spread lessons ... this condition, the International Diabetes Federation (IDF) and Eli ... come together for the second phase of the Bringing ... (BRIDGES 2), reaffirming their commitment to helping people with ...
(Date:6/8/2017)... Texas , June 8, 2017 /PRNewswire/ ... a leading developer and manufacturer of diagnostic ... announced today that Cressey & Company LP ... firm, has completed a growth-focused investment in ... a majority ownership position from selling shareholder, ...
(Date:6/7/2017)... URBANDALE, Iowa , June 6, 2017  Diplomat Specialty Infusion ... a sterile compounding environment to its Iowa ... Urbandale now features an ISO 7 cleanroom—the ... a controlled environment with a low level of pollutants. ... serve more IV nutrition consumers and better serve our ...
Breaking Medicine Technology:
(Date:6/28/2017)... ... June 28, 2017 , ... As we celebrate our ... dog, and that makes it the perfect time to celebrate National Hot Dog Month. ... eat 150 million hot dogs on July 4th alone and while they enjoy many ...
(Date:6/28/2017)... ... 28, 2017 , ... Drs. Steven Crandall, Karen Johnson and Kathy Lopez are ... Upper St. Clair, PA, without a referral. The doctors address jaw pain ... temporomandibular joint and facial muscles that support it. , Jaw pain can be ...
(Date:6/28/2017)... ... June 28, 2017 , ... Eating disorders have the ... 62 minutes, at least one person dies as a direct result from an eating ... exists for qualified treatment providers. The iaedp Foundation meets this challenge by offering what ...
(Date:6/28/2017)... ... June 28, 2017 , ... Park Systems , a leader ... all SEMICONWest attendees and Park customers on July 11, 2017 from 12-2pm ... Sang-il Park, Chairman & CEO of Park Systems, and Prof. Krishna Saraswat , ...
(Date:6/28/2017)... ... June 28, 2017 , ... Designers Insurance Agency, ... in northern Virginia and DC, is announcing a cooperative charity event in conjunction ... and other disorders that lead to memory impairment. , The Insight Memory Care ...
Breaking Medicine News(10 mins):